NLRP3 is a validated anti-inflammatory target that mediates the release of proinflammatory cytokines IL-1β and IL-18, and ISM5059 targets systemic inflammatory conditions by targeting NLRP3 and blocking the inflammatory cascade at its source.

Unlike ISM8969, Insilico’s brain-penetrant NLRP3 pipeline already with FDA IND clearance, ISM5059 features a completely different chemical core designed for peripheral-restricted potency.

Empowered by AI, ISM5059 demonstrated robust efficacy, excellent safety profiles in preclinical studies, and low predicted human efficacious dose, with high potential in multiple indications including autoimmune and chronic cardiometabolic diseases with no obvious CNS (central nervous system) related toxicity observed in preclinical studies.

A new type of brain implant may have implications for both brain research and future treatments of neurological diseases such as epilepsy.

Keck Medicine of USC is conducting an early phase clinical trial investigating the safety and effectiveness of implanting specialized stem cells into the brain that have been programmed to replace damaged brain cells and produce dopamine.  

There is no known cure for Huntington's disease. A genetic mutation creates harmful proteins that accumulate and cause the disease's typical symptoms. A team from the Department of Human Genetics at Ruhr University Bochum has now shown how targeted ubiquitin tagging at two positions in the mutated huntingtin protein affects its breakdown and distribution within the cell. This insight could provide a starting point for future therapies. The team in Bochum, led by Professor Hoa Huu Phuc Nguyen, worked closely with Israeli researcher Professor Aaron Ciechanover, who was awarded the Nobel Prize in Chemistry in 2004 for his work on the protein degradation system. The journal Proceedings of the National Academy of Sciences reports the findings in its issue of January 8, 2026.

Critical care medicine (CCM) in China is entering a new phase with the release of comprehensive national guidelines that redefine how intensive care units (ICUs) are planned, staffed, and managed. Published in Journal of Intensive Medicine on December 30, 2025, the consensus document integrates lessons learned from major public health emergencies with long-term system planning. It proposes tiered standards covering infrastructure, workforce development, quality management, digital transformation, and emergency preparedness, aiming to strengthen resilience, consistency, and equity in critical care delivery across hospitals nationwide.

Researchers have proposed a novel integrated framework to understand the complex progression of autoimmune skin diseases. A review from a team of researchers at the Xijing Hospital, Fourth Military Medical University, China moves beyond studying isolated immune components. It introduces a "time-sequential immune cascade" model combined with a "random multi-hit" theory, offering a fresh lens to view diseases like vitiligo, alopecia areata, psoriasis, and pemphigus vulgaris.